CINECA IRIS Institutional Research Information System

PETRINI, IACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.915
EU - Europa 2.528
AS - Asia 809
AF - Africa 191
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 9.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.755
IT - Italia 1.044
SE - Svezia 533
CN - Cina 491
BG - Bulgaria 284
DE - Germania 190
CI - Costa d'Avorio 165
CA - Canada 159
GB - Regno Unito 133
VN - Vietnam 102
TR - Turchia 78
FI - Finlandia 74
SG - Singapore 72
UA - Ucraina 59
AT - Austria 48
BE - Belgio 41
FR - Francia 34
RU - Federazione Russa 32
IN - India 28
CH - Svizzera 22
AU - Australia 16
SN - Senegal 16
NG - Nigeria 10
NL - Olanda 10
KR - Corea 9
ID - Indonesia 8
PL - Polonia 6
ES - Italia 5
JP - Giappone 5
HK - Hong Kong 4
CZ - Repubblica Ceca 3
HR - Croazia 3
TW - Taiwan 3
IL - Israele 2
IR - Iran 2
MY - Malesia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
IE - Irlanda 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
SA - Arabia Saudita 1
TH - Thailandia 1
Totale 9.462
Salva come PNG Salva come JPEG
Città #
Woodbridge 895
Ann Arbor 786
Houston 716
Fairfield 645
Chandler 427
Serra 362
Seattle 285
Sofia 283
Ashburn 277
Beijing 243
Wilmington 220
Cambridge 216
Milan 175
Abidjan 165
Princeton 150
Ottawa 149
Florence 122
Lawrence 112
Medford 104
Jacksonville 78
Izmir 74
Des Moines 72
Dearborn 68
Pisa 68
Nanjing 56
London 55
San Diego 46
Vienna 43
Bremen 40
Brussels 38
Dong Ket 32
Lancaster 29
Düsseldorf 27
Shenyang 26
Frankfurt am Main 24
Redwood City 24
Nanchang 23
Westminster 22
Hebei 21
Washington 18
Bern 17
Hefei 17
Dakar 16
Changsha 13
Jüchen 13
Kunming 13
Jiaxing 12
Boulder 11
Lucca 11
Lagos 10
Tianjin 10
Boardman 8
Chiesina Uzzanese 8
Guangzhou 8
Chicago 7
Rome 7
Grafing 6
Iowa City 6
Norwalk 6
Phoenix 6
Toronto 6
Camaiore 5
Chengdu 5
Indiana 5
Lugo 5
San Jose 5
Warsaw 5
Wuhan 5
Alessandria 4
Cascina 4
Jakarta 4
Redmond 4
Shanghai 4
Xian 4
Zhengzhou 4
Zurich 4
Auburn Hills 3
Bandung 3
Boston 3
Costa Mesa 3
Hangzhou 3
Hanover 3
Jinan 3
Los Angeles 3
Menlo Park 3
New Bedfont 3
Nürnberg 3
Olgiate Olona 3
Orange 3
Pistoia 3
San Francisco 3
Selargius 3
Seoul 3
Strasbourg 3
Trento 3
Zagreb 3
Amsterdam 2
Anagni 2
Bratislava 2
Carrara 2
Totale 7.562
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 223
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 159
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 152
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 151
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 143
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 143
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 139
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 138
CD57 and γδ T‐cell receptor expression in nodal metastatic spread of melanoma 135
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 132
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 124
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 123
Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. 123
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 122
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors 118
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 118
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 118
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: A brief report 117
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 116
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 112
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 112
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 109
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 109
Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow 107
MDS: An Integrated Workup for a Correct Diagnosis 106
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 106
Oncologia 104
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 104
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 103
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 102
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 102
PET based target volume delineation in hypofractionated radiotherapy in locally advanced NSCLC: A single institution experience 102
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer 102
NUT rearrangement is uncommon in human thymic epithelial tumors 101
Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation 100
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 100
HUMAN MESENCHYMAL CELLS INHIBIT IL2 AND ZOLEDRONATE-INDUCED GAMMA/DELTA T-CELLS. 99
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas 99
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 98
Expression and mutational status of c-kit in thymic epithelial tumors 97
Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells 97
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 96
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 96
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 95
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors 94
Reproducibility of the WHO classification of thymomas: Practical implications 92
Thymic malignancies: From clinical management to targeted therapies 92
Mutations of epigenetic regulatory genes are common in thymic carcinomas 92
null 92
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 91
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 91
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA. 91
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 91
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 91
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 90
Impaired function of gamma-delta lymphocytes in melanoma patients. 89
OCTREOTIDE LAR SUITABLE TREATMENT FOR G1-G2 THORACIC NEUROENDOCRINE TUMORS (T-NET): SINGLE CENTER EXPERIENCE 89
Low RPS14 Expression is frequently found in non 5Q-myelodysplastic syndromes 88
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 88
GAMMA-DELTA T-LYMPHOCYTE SPECIFIC CLONES ARE INVOLVED IN THE GRAFT-VERSUS-MYELOMA AND IN THE GRAFT-VERSUS-HOST DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER NON-MYELOABLATIVE TRANSPLANTATION. 86
Medical treatment of malignant pleural mesothelioma relapses 86
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 86
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 83
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 82
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 81
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma 78
Whole Genome and Transcriptome Sequencing of a B3 Thymoma 77
COMPLETE GENOME SEQUENCING OF A HUMAN B3 THYMOMA 77
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 77
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group 76
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 76
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 74
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 74
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 74
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 74
ErbB in NSCLC as a molecular target: Current evidences and future directions 73
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 72
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer 71
Biology of MET: a double life between normal tissue repair and tumor progression 70
Array comparative genomic hybridization of thymic epithelial tumors identifies loss of CDKN2A as a prognostic factor and BCL2 family members as targets for therapy 67
CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA 66
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA 65
A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. 65
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 65
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma 64
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EOSINOPHILOIA IN EGPA FROM HES 63
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 62
Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment 62
GTF2I MUTATIONS ARE FREQUENT IN THYMIC EPITHELIAL TUMORS 61
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 59
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma 59
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment 57
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 57
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 52
Next generation sequencing of thymomas and thymic carcinomas 52
Reproducibility of the WHO classification for thymomas in relation to prognosis 50
Thymoma: Biology 49
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells 44
Thymectomy in myasthenic patients with thymoma: killing two birds with one stone 42
Surgical treatment of pleural recurrence of thymoma: Is hyperthermic intrathoracic chemotherapy worthwhile? 39
Totale 9.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.868
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.868
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.032 0 0 0 10 65 28 263 16 28 187 238 197
2019/20202.013 210 132 341 128 177 208 211 147 165 121 136 37
2020/2021783 58 42 39 44 53 32 66 57 98 65 94 135
2021/20221.252 32 72 20 52 234 203 42 36 73 60 71 357
2022/20231.688 208 246 113 106 146 177 28 123 339 13 164 25
2023/2024448 147 113 185 3 0 0 0 0 0 0 0 0
Totale 9.725